Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback